DE1910716A1 - Antimikrobielles Arzneimittel und dessen Verwendung - Google Patents
Antimikrobielles Arzneimittel und dessen VerwendungInfo
- Publication number
- DE1910716A1 DE1910716A1 DE19691910716 DE1910716A DE1910716A1 DE 1910716 A1 DE1910716 A1 DE 1910716A1 DE 19691910716 DE19691910716 DE 19691910716 DE 1910716 A DE1910716 A DE 1910716A DE 1910716 A1 DE1910716 A1 DE 1910716A1
- Authority
- DE
- Germany
- Prior art keywords
- phrenosine
- sphingomyelin
- antimicrobial
- weight
- infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004599 antimicrobial Substances 0.000 title claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 14
- 150000003408 sphingolipids Chemical class 0.000 claims description 13
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 230000000845 anti-microbial effect Effects 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 239000007900 aqueous suspension Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 241000304886 Bacilli Species 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002445 nipple Anatomy 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 24
- 238000002255 vaccination Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- 206010041925 Staphylococcal infections Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 108010087702 Penicillinase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70993768A | 1968-03-04 | 1968-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1910716A1 true DE1910716A1 (de) | 1969-10-02 |
Family
ID=24851919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691910716 Pending DE1910716A1 (de) | 1968-03-04 | 1969-03-03 | Antimikrobielles Arzneimittel und dessen Verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3622666A (enrdf_load_stackoverflow) |
| JP (1) | JPS494933B1 (enrdf_load_stackoverflow) |
| CA (1) | CA952017A (enrdf_load_stackoverflow) |
| DE (1) | DE1910716A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2003204A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1259197A (enrdf_load_stackoverflow) |
| NL (1) | NL6903239A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990015609A1 (en) * | 1989-06-15 | 1990-12-27 | Med-Tal, Inc. | Prevention and treatment of microbial infection by phosphoglycerides |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK17885D0 (da) * | 1985-01-14 | 1985-01-14 | Karlsson Karl Anders | Antiviralt middel |
| TW261533B (enrdf_load_stackoverflow) * | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| KR100301890B1 (ko) * | 1997-02-05 | 2002-01-09 | 사토 야스히로 | 스핀고당지질을함유하는동결건조조성물및그의제조방법 |
| NL1022443C2 (nl) * | 2003-01-20 | 2004-07-22 | Tno | Sphingolipiden voor verbetering van de samenstelling van de darmflora. |
| KR101442047B1 (ko) * | 2005-09-22 | 2014-09-18 | 유키지루시 메그밀크 가부시키가이샤 | 스핑고미엘린 함유 의약, 음식품 또는 사료 |
-
1968
- 1968-03-04 US US709937A patent/US3622666A/en not_active Expired - Lifetime
-
1969
- 1969-03-03 DE DE19691910716 patent/DE1910716A1/de active Pending
- 1969-03-03 JP JP44015459A patent/JPS494933B1/ja active Pending
- 1969-03-03 NL NL6903239A patent/NL6903239A/xx unknown
- 1969-03-04 FR FR6905874A patent/FR2003204A1/fr not_active Withdrawn
- 1969-03-04 CA CA044,623A patent/CA952017A/en not_active Expired
- 1969-03-04 GB GB1259197D patent/GB1259197A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990015609A1 (en) * | 1989-06-15 | 1990-12-27 | Med-Tal, Inc. | Prevention and treatment of microbial infection by phosphoglycerides |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS494933B1 (enrdf_load_stackoverflow) | 1974-02-04 |
| GB1259197A (enrdf_load_stackoverflow) | 1972-01-05 |
| US3622666A (en) | 1971-11-23 |
| FR2003204A1 (enrdf_load_stackoverflow) | 1969-11-07 |
| NL6903239A (enrdf_load_stackoverflow) | 1969-09-08 |
| CA952017A (en) | 1974-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2265533C2 (de) | Antibakterielles Mittel | |
| DE3873603T2 (de) | Zusammensetzung gegen coccidiosis. | |
| DE2746974A1 (de) | Verwendung der pseudomonsaeure und ihrer salze und ester | |
| DE1910716A1 (de) | Antimikrobielles Arzneimittel und dessen Verwendung | |
| DE2208787A1 (de) | Virusheilmittel | |
| DE2751454A1 (de) | Steuerung und umkehr der immunologischen alterung | |
| DE2608079A1 (de) | Arzneipraeparat in form eines trockenpraeparats zur herstellung von injektionen | |
| EP0398165A1 (de) | Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe | |
| DE2824610C2 (de) | Arzneimittelgemisch aus einer Penicillansäure und aus einem Penicillin oder Cephalosporin | |
| DE1900697A1 (de) | Antibiotische Arzneimittel und Verfahren zum Herstellen von Antikoerpern | |
| DD143729A5 (de) | Verfahren zur herstellung eines immunbiotherapeutischen arzneimittels gegen infektionen der atemwege | |
| DE2445679C3 (de) | Stimulierung der Immunität | |
| DE2727236C3 (de) | Verfahren zum Herstellen von Lösungen filtrierter Lysate und darauf basierendes, oral applizierbares Arzneimittel zum Vorbeugen gegen und Bekämpfen von Zahnkaries und Paradentoseerkrankungen | |
| DE2036113C3 (de) | Wäßriges Tetramisolpräparat | |
| DE2521922A1 (de) | Pharmazeutisches mittel | |
| DE19828596A1 (de) | Wirksames Arzneimittel gegen bakterielle Erkrankungen und Herstellung desselben | |
| DE1617659B2 (de) | Interferonbildendes Arzneimittel und dessen Verwendung | |
| DE1792223C3 (de) | Arzneipräparate, geeignet zur Behandlung von durch gramnegative Bakterien hervorgerufenen Infektionen | |
| DE2149602A1 (de) | Arzneimittel zur verleihung von widerstandsfaehigkeit gegen bakterielle infektionen | |
| DE2122278A1 (de) | Verfahren zum Haltbarmachen von Antiacidum-Zusammensetzungen | |
| DE550833C (de) | Verfahren zur UEberfuehrung von Bakterienpraeparaten, Bakterienextrakten, Toxinen, Sera u. dgl. in haltbare, die Haut und die Schleimhaeute leicht durchdringende Produkte | |
| EP0304897A2 (de) | Mittel zur Immunisierung des menschlichen Körpers bei HIV-Infektionen | |
| DE2128249C3 (de) | Verfahren zur Herstellung eines gegen Staphylococcus aureus hämolvtkus in der Mund und Nasenhöhle wirksamen, per os einzunehmenden Arzneimittels | |
| DE2413803A1 (de) | Pharmazeutische zusammensetzungen aus gemischten salzen von sulfoglykopeptiden mit metallbasen und organischen basen | |
| DE2650608A1 (de) | Arzneipraeparat zur behandlung von mastitis bei milchvieh |